Drug-Induced Tubulointerstitial Nephritis: Insights From the World Health Organization Safety Database

Alexandre O. Gérard, Diane Merino, Audrey Laurain, Marion Cremoni, Marine Andreani, Fanny Rocher, Alexandre Destere, Vincent L.M. Esnault, Antoine Sicard, and Milou-Daniel Drici

1Department of Nephrology-Dialysis-Transplantation, University Hospital Centre of Nice, Nice, France; 2Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital Centre of Nice, Nice, France; 3Laboratory of Molecular Physiomedicine (LP2M), UMR 7370, Centre National de la Recherche Scientifique, University Côte d’Azur, Nice, France; 4Department of Immunology, University Hospital Centre of Nice, Nice, France; and 5Clinical Research Unit of University Côte d’Azur (UR2CA), University Côte d’Azur, Nice, France

Correspondence: Milou-Daniel Drici, Department of Pharmacology and Pharmacovigilance, Pasteur Hospital, Bât J4, 30 Avenue de la Voie Romaine—CS51069, 06001 Nice Cedex 01, France. E-mail: pharmacovigilance@chu-nice.fr

6AS and MDD contributed equally to this work as the last authors.

Received 14 March 2022; revised 19 April 2022; accepted 22 April 2022; published online 5 May 2022

Kidney Int Rep (2022) 7, 1699–1702; https://doi.org/10.1016/j.ekir.2022.04.090

KEYWORDS: allergy; database; drugs; nephrotoxicity; pharmacovigilance; tubulointerstitial nephritis

© 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

INTRODUCTION

Tubulointerstitial nephritis (TIN) is characterized by renal failure associated with an array of histologic lesions relating to an infiltration of inflammatory cells in the kidney interstitium with edema, often accompanied by tubulitis. The histologic pattern can also evolve into fibrosis, especially if TIN is left undiagnosed. TIN can arise from infections or autoimmune diseases (lupus, Sjögren, sarcoidosis, IgG4-related disease, etc.), but the most common cause remains an immune-mediated reaction to drugs, accounting for more than two-thirds of cases. Drug-induced TIN accounts for 3% to 15% of renal biopsy samples. This number increases up to 27% when only patients with unexplained acute renal failure are considered.

The presumptive diagnosis is often challenging, given the heterogeneous clinical picture. TIN is typically characterized by a (sub)acute rise in creatinine, which is seldom specific. Besides, there is often no abnormality in the urinalysis. Therefore, anamnesis is pivotal to the early diagnosis. Etiologic investigations should rely on a thorough knowledge of the most suspect drugs, to promptly discontinue the possible culprit. Furthermore, early treatment with steroids may speed renal recovery.

Yet, quantitative and qualitative data about the association of TIN with various drugs are scarce. Therefore, we aimed to rank the drugs having the strongest association with TIN, based on the international pharmacovigilance database and a disproportionality analysis.

RESULTS

Characteristics of the Reports

Between November 14, 1967, and August 31, 2021, a total of 15,696 cases of TIN (Preferred Term from the Medical Dictionary for Regulatory Activities, MedDRA) were reported in VigiBase (Supplementary Material for Methods). The most represented age group was the 45- to 64-year-old group with 4075 reports (35.3%), and the median age was 60 years (interquartile range: 43–71). Men were involved in 6881 reports (53.1%). The United States of America contributed 7959 reports (50.7%). Notifiers were healthcare professionals in 9667 reports (61.6%). Detailed characteristics are provided in Table 1.

Characteristics of the TIN

Among 15,696 reports, 12,481 (79.5%) were deemed serious, including 977 fatal cases (6.2%). The median time to onset was 20 (interquartile range: 5–103) days. The MedDRA terms most frequently co-reported were acute kidney injury, in 6350 reports (35.3%), and the median age was 60 years (interquartile range: 43–71). Men were involved in 6881 reports (53.1%). The United States of America contributed 7959 reports (50.7%). Notifiers were healthcare professionals in 9667 reports (61.6%). Detailed characteristics are provided in Table 1.
(375 reports, 2.4%), and eosinophilia (320 reports, 2.0%) were the most frequently coreported extrarenal terms. Among 8221 cases with an available outcome, TIN completely recovered in 3019 reports (36.7%), did not recover in 2676 reports (32.6%), and was recovering or recovered with sequelae (without returning to baseline kidney function) in 2526 reports (30.7%).

Active Ingredients Ranked by Absolute Number of Reports

Most of the reported drugs belong to the “alimentary tract and metabolism” and the “antineoplastics for systemic use” categories (Anatomical Therapeutic Chemical classification system), with 8204 (52.3%) and 4525 (28.8%) notifications, respectively. Specifically, proton pump inhibitors (PPIs) were the most frequently reported drugs, with 5769 reports (36.8%). Omeprazole was the most reported (4328, 27.6%), followed by lansoprazole and esomeprazole. Aside from PPIs, the most reported active ingredient was ciprofloxacin with 529 reports (3.4%), followed by ibuprofen (497, 3.2%), vancomycin (430, 2.7%), diclofenac (299, 1.9%), and sulfamethoxazole/trimethoprim (292, 1.9%). As a whole, β-lactams accounted for 1461 reports.

Disproportionality Analysis

In the disproportionality analysis, 223 active ingredients were characterized by a positive IC025. PPI (as a whole: reporting odds ratio [ROR] 57.3; 95% CI 55.5–59.2) reached the 9 strongest ROR, including dexamethasone (ROR 209.9; 95% CI 200.0–220.3), lansoprazole (ROR 134.1; 95% CI 129.1–139.3), and rabeprazole (ROR 127.3; 95% CI 119.6–135.4), inter alia. Penicillin antibiotics, such as nafcillin (ROR 63.2; 95% CI 51.0–78.3) and fluoxacillin (ROR 31.4; 95% CI 27.3–36.0), were also characterized by strong ROR. As a whole, β-lactam was characterized by a ROR of 4.8 (95% CI 4.6–5.1). Other drugs significantly associated with TIN included sodium phosphate (ROR 55.6; 95% CI 45.3–68.4) and mesalazine (ROR 35.0; 95% CI 31.6–38.8). The ranking of active ingredients with IC025 > 0 and ≥30 reports is provided in Table 2.

DISCUSSION

Although virtually any drug can be associated with a risk of TIN, this analysis of the World Health Organization safety database highlights the most frequently involved. These drugs should alert the clinician facing suspicion of TIN or acute renal failure of undetermined cause. PPIs, antibiotics, and nonsteroidal anti-inflammatory drugs are the most reported drugs for TIN. This ranking is confirmed by the disproportionality analysis, which is a more reliable indicator of the comparative risk for a drug to be associated with TIN.

Previous studiesS1–S3 suggested that TIN was more frequent in the elderly. Indeed, their reduced renal function makes them prone to the accumulation of drugs and metabolites. They are also exposed to a wider range of drugs. In VigiBase, half of the reports concerned patients > 60 years of age. Half of the

---

### Table 1. Characteristics of the reports of patients with tubulointerstitial nephritis

| Characteristics | Number of reports (%) |
|-----------------|-----------------------|
| **Age**         |                       |
| ≤23 mo          | 52 (0.5)              |
| 2–11 yr         | 235 (2.0)             |
| 12–17 yr        | 554 (4.8)             |
| 18–44 yr        | 2143 (18.6)           |
| 45–64 yr        | 4075 (35.3)           |
| 65–74 yr        | 2459 (21.3)           |
| ≥75 yr          | 2030 (17.8)           |

| **Country**     | Number of reports (%) |
|-----------------|-----------------------|
| United States   | 7959 (50.7)           |
| Japan           | 1251 (8.0)            |
| United Kingdom  | 990 (6.3)             |
| France          | 972 (6.2)             |
| Australia       | 705 (4.5)             |
| Spain           | 520 (3.3)             |
| Germany         | 484 (3.1)             |
| Canada          | 437 (2.8)             |
| Sweden          | 257 (1.6)             |
| Switzerland     | 231 (1.5)             |

| **Reporter qualification** | Number of reports (%) |
|----------------------------|-----------------------|
| Physician                  | 6062 (38.6)           |
| Pharmacist                 | 1487 (9.5)            |
| Other health professional  | 2118 (13.5)           |
| Lawyer                     | 1175 (7.5)            |
| Consumer                   | 1551 (9.9)            |
| Unknown                    | 3671 (23.4)           |

### Table 2. Active ingredients disproportionately reported (IC025 >0) with tubulointerstitial nephritis, ranked by number of reports (only the 15 most reported drugs are displayed, see Supplementary Table S1 for a more comprehensive listing)

| Active Ingredient       | Number of reports (%) | ROR (95% CI) |
|-------------------------|-----------------------|--------------|
| Omeprazole              | 4328 (27.6)           | 84.5 (81.6–87.6) |
| Lansoprazole            | 3571 (22.8)           | 134.1 (129.1–139.3) |
| Esomeprazole            | 3532 (22.5)           | 79.6 (76.7–82.7) |
| Pantoprazole            | 3185 (20.3)           | 100 (96.2–104.1) |
| Dexamethasone           | 2067 (13.2)           | 209.9 (200–220.3) |
| Rabeprazole             | 1142 (7.3)            | 127.3 (119.6–135.4) |
| Ciprofloxacin           | 529 (3.4)             | 7.9 (7.3–8.7) |
| Ibuprofen               | 497 (3.2)             | 5.3 (4.9–5.8) |
| Vancocymycin            | 430 (2.7)             | 10.8 (9.8–11.9) |
| Pantoprazole/hexobactam | 399 (2.5)             | 11.8 (10.7–13.1) |
| Mesalazine              | 387 (2.5)             | 35 (31.6–38.8) |
| Esomeprazole/naproxen   | 309 (2)               | 64.4 (57.5–72.2) |
| Diclofenac              | 299 (1.9)             | 3.5 (3.2–4) |
| Nivolumab               | 293 (1.9)             | 9.7 (8.6–10.9) |
| Sulfamethoxazole/trimethoprim | 292 (1.9) | 4.2 (3.7–4.7) |

ROR, reporting odds ratio.
reported TINs occurred during the first 3 weeks of treatment, whereas 1 quarter occurred after >3 months. Thus, the time to onset may be slightly longer than previously described. S3, S54 In our retrospective study, approximately one-third of patients recovered completely, which is in the lower range of what has been previously reported (between one- and two-thirds of complete recoveries). S6, S33, S54 Besides, >1 quarter of the patients ended up with chronic kidney disease.

As expected, S6, S67 PPIs account for more than one-third of TIN reports in VigiBase. The magnitude of their reporting is likely subsequent to their wide use, exposing a large share of the population to their adverse effects. Their strong association with TIN stands out even in the disproportionality analysis, which includes the total number of adverse drug reactions notified with a given drug.

In line with previous studies, S2, S56 antibiotics are also frequently reported, especially fluoroquinolones (e.g., ciprofloxacin) and β-lactams. Some are widely used, such as amoxicillin, mechanically increasing the absolute number of reports. Conversely, barely used β-lactams, such as nafcillin, are associated with a strong disproportionality signal. Regarding vancomycin, there is a signal regarding its association with immune-allergic TIN, beyond the well-known cases of acute tubular necrosis, possibly associated with tubular casts. S9– S12

The association of nonsteroidal anti-inflammatory drugs (e.g., ibuprofen) with TIN was foreseeable. S6, S66, S13–S15 Their ROR may be underestimated, because they are involved in many other renal and extrarenal adverse drug reactions. As for immune checkpoint inhibitors (e.g., nivolumab), their association with TIN is confirmed, even though the exact underlying mechanism is still debated. S16, S20钠磷灰石 can elicit acute or chronic phosphate nephropathy, S21 which pathophysiology is totally different from common drug-induced TIN (of immunoallergic mechanism).

To our knowledge, this study about TIN is the first to rely on a comprehensive analysis of >15,000 reports from the World Health Organization safety database, with drugs used in a real-life setting. Though, pharmacovigilance studies are hindered by under-reporting. S22 Conversely, we cannot exclude that some diagnoses of TIN might have been wrongly attributed to the notified drug. A confirmation of the diagnosis by renal biopsy may have lacked in some cases, as these data are not provided in VigiBase. In fact, incomplete data are inherent to pharmacovigilance studies and hinder thorough qualitative assessments of the reports. For instance, the rate of recovery may have been slightly higher if patients classified as recovering had been followed longer. The MedDRA terminology, used in VigiBase, prevented us from fully discriminating between acute and chronic forms of TIN. Besides, clinicians are prone to ascribe a TIN diagnosis to a drug already known to cause TIN (reporting bias). Thus, to partly mitigate this potential confirmation bias, the ranking according to the absolute number of reports was underpinned by a disproportionality analysis. The large sample size may partly compensate the qualitative heterogeneity of data. Overall, those pharmacovigilance approaches can only suggest and compare safety signals and do not allow to conclude on a causal association between an effect and a given drug.

In this comprehensive analysis of the World Health Organization safety database, a ranking of drugs associated with TIN has been established. The strongest associations with TIN involve PPIs, antibiotics (β-lactams, fluoroquinolones, glycopeptides), and nonsteroidal anti-inflammatory drugs. Early identification of a potential causative drug is pivotal to increase chances of recovery. Hence, pharmacovigilance data can foster the efficient management of (sub)acute renal failure of undetermined origin.

**DISCLOSURE**

All the authors declared no competing interests.

**ACKNOWLEDGMENTS**

The authors acknowledge the UMC who manages and provided the data used in the present study. Access to VigiBase is available without fees to Dr. Fanny Rocher. The views expressed in this article are the authors’ personal views and may not be understood or quoted as being made on behalf of or reflect the position of the Agence nationale de sécurité du médicament et des produits de santé, the European Medicines Agency, the World Health Organization, or one of their committees or working parties. The authors thank Dr. Elise Van Obberghen (MD), a native speaker of American English, for proofreading this manuscript. She received no compensation for this work.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from VigiBase. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from Fanny Rocher, without fees, with the permission of Uppsala Monitoring Centre.

**AUTHOR CONTRIBUTIONS**

AOG, DM, AL, MC, MA, FR, AD, VLME, AS, and MDD wrote the manuscript. AOG, DM, AS, and MDD designed the
research. AOG, DM, and FR performed the research. AOG and DM analyzed the data.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

Supplementary Methods.

Supplementary References.

**Table S1.** Active ingredients disproportionately reported (IC0.25 > 0) with tubulointerstitial nephritis, ranked by number of reports (only active ingredients involved in ≥30 reports are displayed).

**REFERENCES**

1. Toto RD. Review: acute tubulointerstitial nephritis. *Am J Med Sci.* 1990;299:392–410. https://doi.org/10.1097/00000441-19906000-00007

2. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. *Nephrol Dial Transplant.* 2004;19:8–11. https://doi.org/10.1093/ndt/gfg464

3. Clarkson MR, Giblin L, O’Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. *Nephrol Dial Transplant.* 2004;19:2778–2783. https://doi.org/10.1093/ndt/gfh485

4. Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. *Am J Kidney Dis.* 2000;35:433–447. https://doi.org/10.1016/s0272-6386(00)70196-x

5. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. *Nat Rev Nephrol.* 2010;6:461–470. https://doi.org/10.1038/nrneph.2010.71

6. García M, Saracho R, Jaio N, Vrotsoukanari K, Aguirre C. Inadequate drug prescription and the rise in drug-induced acute tubulointerstitial nephritis incidence. *NDT Plus.* 2010;3:555–557. https://doi.org/10.1093/ndtplus/sfq146